Not all leaders are good leaders.Perhaps you’ve lost an important executive or you’re establishing a local leadership team. You know that the leader you choose will have a major impact on the organization. So how can you avoid hiring the…
HOME > BUSINESS
BUSINESS
- Otsuka/Lundbeck Seek PTSD Nod for Rexulti in US
April 10, 2024
- US FDA Grants Orphan Exclusivity for ALS Drug Radicava ORS
April 10, 2024
- R&D Jobs Make Up 40% of Pharma New Grads Hires This Spring, Sales Reps Only 20%: Poll
April 9, 2024
- Toray Nets Positive Preclinical Data in Polymer-Conjugated Cancer Drug
April 9, 2024
- Renalys Submits IND for Japan PIII Study of IgA Nephropathy Drug
April 9, 2024
- Janssen Files Amivantamab Plus Lazertinib for NSCLC in Japan
April 9, 2024
- Enhertu Nabs Pan-Tumor Indication in US: Daiichi Sankyo
April 9, 2024
- GSK Japan Shooting for 80% Goal for Paid Paternity Leave in 2024
April 8, 2024
- Otsuka, Verily Join Forces to Run Mental Health Registry
April 8, 2024
- Japan Ethical Drug Sales Zoom 12.1% in February: Crecon
April 8, 2024
- Keytruda Tops Japan Sales List for 6th Month in March: Encise
April 8, 2024
- Kyowa Kirin Hopes Amgen-Partnered Eczema Drug to Rival or Even Eclipse Crysvita in Sales: CEO
April 5, 2024
- Rohto, Mitsui to Buy Singapore’s Chinese Medicine Firm for SGD800 Million
April 5, 2024
- Nippon Shinyaku, MiNA Therapeutics Join Hands in Rare CNS Disorders
April 5, 2024
- Healios Snaps Up Assets after Athersys’ Bankruptcy Filing
April 5, 2024
- Tarlige Winner in February GP Rep Promotion Rankings
April 4, 2024
- Taisho’s Positive PIII Data Set Stage for Japan Filing of Insomnia Med
April 4, 2024
- FDA OKs First Digital Therapeutic App for Depression: Otsuka
April 4, 2024
- Chugai Offers 5% Pay Raise in 30-Year-Old Model Case
April 4, 2024
- Mochida, Meiji Adds China for Epadel Sales Collaboration
April 4, 2024
ページ
Earlier this month, Health Minister Keizo Takemi called on the top executives of 13 major generic makers to restructure the industry with a product consolidation target of “around five companies per API.” While a variety of restructuring options are conceivable,…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…